Medicenna Therapeutics Corp. (TSE:MDNA - Get Free Report)'s share price dropped 4.5% on Friday . The stock traded as low as C$0.82 and last traded at C$0.84. Approximately 17,872 shares changed hands during trading, a decline of 61% from the average daily volume of 45,469 shares. The stock had previously closed at C$0.88.
Medicenna Therapeutics Price Performance
The company has a debt-to-equity ratio of 0.88, a current ratio of 11.40 and a quick ratio of 4.65. The stock has a market capitalization of C$59.85 million, a P/E ratio of -2.20 and a beta of 1.21. The company's 50 day simple moving average is C$0.94 and its two-hundred day simple moving average is C$1.07.
About Medicenna Therapeutics
(
Get Free Report)
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.
Further Reading
Before you consider Medicenna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medicenna Therapeutics wasn't on the list.
While Medicenna Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access